Literature DB >> 28009290

Inhibition of RORγT Skews TCRα Gene Rearrangement and Limits T Cell Repertoire Diversity.

Yanxia Guo1, Kenzie D MacIsaac2, Yi Chen1, Richard J Miller2, Renu Jain1, Barbara Joyce-Shaikh1, Heidi Ferguson2, I-Ming Wang3, Razvan Cristescu1, John Mudgett4, Laura Engstrom2, Kyle J Piers2, Gretchen A Baltus2, Kenneth Barr2, Hongjun Zhang2, Huseyin Mehmet2, Laxminarayan G Hegde2, Xiao Hu5, Laura L Carter5, Thomas D Aicher5, Gary Glick5, Dennis Zaller2, Abbas Hawwari6, Craig C Correll2, Dallas C Jones2, Daniel J Cua7.   

Abstract

Recent studies have elucidated the molecular mechanism of RORγT transcriptional regulation of Th17 differentiation and function. RORγT was initially identified as a transcription factor required for thymopoiesis by maintaining survival of CD4+CD8+ (DP) thymocytes. While RORγ antagonists are currently being developed to treat autoimmunity, it remains unclear how RORγT inhibition may impact thymocyte development. In this study, we show that in addition to regulating DP thymocytes survival, RORγT also controls genes that regulate thymocyte migration, proliferation, and T cell receptor (TCR)α selection. Strikingly, pharmacological inhibition of RORγ skews TCRα gene rearrangement, limits T cell repertoire diversity, and inhibits development of autoimmune encephalomyelitis. Thus, targeting RORγT not only inhibits Th17 cell development and function but also fundamentally alters thymic-emigrant recognition of self and foreign antigens. The analysis of RORγ inhibitors has allowed us to gain a broader perspective of the diverse function of RORγT and its impact on T cell biology.
Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  RORγT; T cell repertoire; autoimmunity; experimental autoimmune encephalomyelitis; experimental psoriasis; small-molecule antagonist; thymopoiesis

Mesh:

Substances:

Year:  2016        PMID: 28009290     DOI: 10.1016/j.celrep.2016.11.073

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  22 in total

1.  Discovery of N-(Indazol-3-yl)piperidine-4-carboxylic Acids as RORγt Allosteric Inhibitors for Autoimmune Diseases.

Authors:  Hongjun Zhang; Blair T Lapointe; Neville Anthony; Rita Azevedo; Jos Cals; Craig C Correll; Matthew Daniels; Sujal Deshmukh; Hans van Eenenaam; Heidi Ferguson; Laxminarayan G Hegde; Willem Jan Karstens; John Maclean; J Richard Miller; Lily Y Moy; Vladimir Simov; Sunil Nagpal; Arthur Oubrie; Rachel L Palte; Gopal Parthasarathy; Nunzio Sciammetta; Mario van der Stelt; Janice D Woodhouse; B Wesley Trotter; Kenneth Barr
Journal:  ACS Med Chem Lett       Date:  2020-01-09       Impact factor: 4.345

2.  Analysis of the Transcriptional Activity of Retinoic Acid-Related Orphan Receptors (RORs) and Inhibition by Inverse Agonists.

Authors:  Yukimasa Takeda; Hong Soon Kang; Anton M Jetten
Journal:  Methods Mol Biol       Date:  2019

3.  Interleukin-23 deficiency alters thymic selection in lupus-prone mice.

Authors:  H Dai; V C Kyttaris
Journal:  Lupus       Date:  2019-06-05       Impact factor: 2.911

4.  Small-Molecule RORγt Antagonists: One Stone Kills Two Birds.

Authors:  Chao Zhong; Jinfang Zhu
Journal:  Trends Immunol       Date:  2017-02-28       Impact factor: 16.687

5.  Human gut bacterial metabolism drives Th17 activation and colitis.

Authors:  Margaret Alexander; Qi Yan Ang; Renuka R Nayak; Annamarie E Bustion; Moriah Sandy; Bing Zhang; Vaibhav Upadhyay; Katherine S Pollard; Susan V Lynch; Peter J Turnbaugh
Journal:  Cell Host Microbe       Date:  2021-11-24       Impact factor: 21.023

6.  T-bet and RORα control lymph node formation by regulating embryonic innate lymphoid cell differentiation.

Authors:  Jakob Zimmermann; Chiara Romagnani; Christina Stehle; Timo Rückert; Rémi Fiancette; Dominika W Gajdasik; Claire Willis; Carolin Ulbricht; Pawel Durek; Mir-Farzin Mashreghi; Daniela Finke; Anja Erika Hauser; David R Withers; Hyun-Dong Chang
Journal:  Nat Immunol       Date:  2021-09-23       Impact factor: 25.606

7.  Conformational Changes of RORγ During Response Element Recognition and Coregulator Engagement.

Authors:  Timothy S Strutzenberg; Yingmin Zhu; Scott J Novick; Ruben D Garcia-Ordonez; Christelle Doebelin; Yuanjun He; Mi Ra Chang; Theodore M Kamenecka; Dean P Edwards; Patrick R Griffin
Journal:  J Mol Biol       Date:  2021-09-20       Impact factor: 5.469

8.  Inhibition of the transcription factor ROR-γ reduces pathogenic Th17 cells in acetylcholine receptor antibody positive myasthenia gravis.

Authors:  John S Yi; Melissa A Russo; Shruti Raja; Janice M Massey; Vern C Juel; Jay Shin; Lisa D Hobson-Webb; Karissa Gable; Jeffrey T Guptill
Journal:  Exp Neurol       Date:  2019-12-12       Impact factor: 5.330

9.  A dysbiotic microbiome triggers TH17 cells to mediate oral mucosal immunopathology in mice and humans.

Authors:  Nicolas Dutzan; Tetsuhiro Kajikawa; Loreto Abusleme; Teresa Greenwell-Wild; Carlos E Zuazo; Tomoko Ikeuchi; Laurie Brenchley; Toshiharu Abe; Charlotte Hurabielle; Daniel Martin; Robert J Morell; Alexandra F Freeman; Vanja Lazarevic; Giorgio Trinchieri; Patricia I Diaz; Steven M Holland; Yasmine Belkaid; George Hajishengallis; Niki M Moutsopoulos
Journal:  Sci Transl Med       Date:  2018-10-17       Impact factor: 17.956

10.  Retinoic acid-related Orphan Receptor γ (RORγ): connecting sterol metabolism to regulation of the immune system and autoimmune disease.

Authors:  Anton M Jetten; Yukimasa Takeda; Andrzej Slominski; Hong Soon Kang
Journal:  Curr Opin Toxicol       Date:  2018-02-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.